anti-CD19 antibody-T-cell receptor-expressing T cells ET019003
Term · Oncology and biomedicine · MLC-T-ONC-010250
A preparation of T lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.
| Identifier | MLC-T-ONC-010250 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ET019003-T cells; anti-CD19 AbTCR-expressing T cells ET019003; anti-CD19 T cells ET019003; CD19-targeted T cells ET019003; anti-CD19-TCR T cells ET019003 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010250",
"term": "anti-CD19 antibody-T-cell receptor-expressing T cells ET019003",
"field": "Oncology and biomedicine",
"definition": "A preparation of T lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.",
"synonyms": [
"ET019003-T cells",
"anti-CD19 AbTCR-expressing T cells ET019003",
"anti-CD19 T cells ET019003",
"CD19-targeted T cells ET019003",
"anti-CD19-TCR T cells ET019003"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd19-antibody-t-cell-receptor-expressing-t-cells-et019003/"
}
Record 1,335 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.